Should I buy or sell Singular Genomics Systems stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Singular Genomics Systems in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OMIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMIC, but not buy additional shares or sell existing shares. View OMIC analyst ratings or view top-rated stocks .

What is Singular Genomics Systems' stock price target for 2024?

2 brokers have issued 1-year price objectives for Singular Genomics Systems' stock. Their OMIC share price targets range from $0.50 to $0.85. On average, they predict the company's stock price to reach $0.68 in the next twelve months. This suggests a possible upside of 79.0% from the stock's current price. View analysts price targets for OMIC or view top-rated stocks among Wall Street analysts .

How have OMIC shares performed in 2024?

Singular Genomics Systems' stock was trading at $0.4601 at the beginning of the year. Since then, OMIC shares have decreased by 18.1% and is now trading at $0.3770. View the best growth stocks for 2024 here .

When is Singular Genomics Systems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our OMIC earnings forecast .

How were Singular Genomics Systems' earnings last quarter?

Singular Genomics Systems, Inc. (NASDAQ:OMIC) issued its quarterly earnings data on Monday, March, 18th. The company reported ($0.34) earnings per share for the quarter. The company had revenue of $1.08 million for the quarter. Singular Genomics Systems had a negative net margin of 3,257.30% and a negative trailing twelve-month return on equity of 45.33%.

When did Singular Genomics Systems IPO?

Singular Genomics Systems (OMIC) raised $178 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen and UBS Investment Bank served as the underwriters for the IPO.

How do I buy shares of Singular Genomics Systems?

Shares of OMIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OMIC

Singular Genomics Systems (OMIC) Stock Price, News & Analysis

→ The #1 Investment of the Decade… (From Porter & Company) (Ad)

Free OMIC Stock Alerts

$0.38

-0.05 (-11.71%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.38
▼
$0.43
50-Day Range: $0.38
▼
$0.61
52-Week Range: $0.31
▼
$1.21

Volume: 128,664 shs
Average Volume: 115,172 shs
Market Capitalization: $27.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $0.68

Get Singular Genomics Systems alerts:

Singular Genomics Systems MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 79.0% Upside
$0.68 Price Target
Short Interest: Healthy
1.73% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.94
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.77 out of 5 stars

Medical Sector

416th out of 929 stocks

Analytical Instruments Industry

16th out of 28 stocks

3.0

Analyst's Opinion

Consensus Rating
Singular Genomics Systems has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Singular Genomics Systems has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.73% of the float of Singular Genomics Systems has been sold short.
Short Interest Ratio / Days to Cover
Singular Genomics Systems has a short interest ratio ("days to cover") of 7.1.
Change versus previous month
Short interest in Singular Genomics Systems has recently decreased by 9.98%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Singular Genomics Systems does not currently pay a dividend.
Dividend Growth
Singular Genomics Systems does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OMIC.

2.7

News and Social Media Coverage

News Sentiment
Singular Genomics Systems has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Singular Genomics Systems this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added Singular Genomics Systems to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Singular Genomics Systems insiders have not sold or bought any company stock.
Percentage Held by Insiders
22.60% of the stock of Singular Genomics Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
65.80% of the stock of Singular Genomics Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Singular Genomics Systems is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Singular Genomics Systems is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Singular Genomics Systems has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Singular Genomics Systems Stock (NASDAQ:OMIC)

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.

OMIC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OMIC Stock News Headlines

April 12, 2024 | americanbankingnews.com

Singular Genomics Systems (NASDAQ:OMIC) Trading Down 5.4%

April 4, 2024 | msn.com

Deciphering genomic language: New AI system unlocks biology’s source code

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

March 20, 2024 | seekingalpha.com

Singular Genomics Systems, Inc. (OMIC) Q4 2023 Earnings Call Transcript

March 20, 2024 | finance.yahoo.com

Singular Genomics Systems, Inc. (NASDAQ:OMIC) Q4 2023 Earnings Call Transcript

March 19, 2024 | finanznachrichten.de

Singular Genomics Systems, Inc.: Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results

March 18, 2024 | benzinga.com

Singular Genomics Sys: Q4 Earnings Insights

March 18, 2024 | globenewswire.com

Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

March 17, 2024 | markets.businessinsider.com

Singular Genomics Systems earnings: here's what to expect

March 15, 2024 | benzinga.com

Preview: Singular Genomics Sys's Earnings

March 15, 2024 | msn.com

Single-cell RNA-seq reveals transcriptomic modulation of Alzheimer's disease by activated protein C

March 11, 2024 | msn.com

Novel gene editing tool analyzes sperm health in animals

March 5, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA), ZimVie Inc (ZIMV) and Veeva Systems (VEEV)

March 4, 2024 | globenewswire.com

Singular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024

February 24, 2024 | wsj.com

Singular Genomics Systems Inc.

February 5, 2024 | finanznachrichten.de

Singular Genomics Systems, Inc.: Singular Genomics Unveils G4X Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis

January 8, 2024 | msn.com

Singular Genomics reports instrument shipments, preliminary Q4 revenue

January 7, 2024 | finance.yahoo.com

Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue

January 4, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Pfizer (PFE) and Neurogene (NGNE)

November 21, 2023 | finance.yahoo.com

Singular Genomics Systems Founder Acquires 4.6% More Stock

November 16, 2023 | markets.businessinsider.com

Hold Rating on Singular Genomics Systems (OMIC) Amid Q3 Underperformance and Strategy Shift

November 16, 2023 | finanznachrichten.de

Singular Genomics Systems, Inc.: Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial Results

November 14, 2023 | benzinga.com

Recap: Singular Genomics Sys Q3 Earnings

November 14, 2023 | seekingalpha.com

OMIC Singular Genomics Systems, Inc.

November 4, 2023 | morningstar.com

Singular Genomics Systems Inc OMIC

October 24, 2023 | finance.yahoo.com

Singular Genomics to Report Third Quarter 2023 Financial Results on November 14, 2023

See More Headlines

Receive OMIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Singular Genomics Systems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:OMIC
CUSIP: N/A
CIK: 1850906
Web: singulargenomics.com
Phone: 858-333-7830
Fax: N/A
Employees: 255
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $0.68
High Stock Price Target: $0.85
Low Stock Price Target: $0.50
Potential Upside/Downside: +63.0%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-94,820,000.00
Net Margins: -3,257.30%
Pretax Margin: -3,257.30%
Return on Equity: -45.33%
Return on Assets: -33.29%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 10.51
Quick Ratio: 9.77

Sales & Book Value

Annual Sales: $2.91 million
Price / Sales: 10.52
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.44 per share
Price / Book: 0.17

Miscellaneous

Outstanding Shares: 73,930,000
Free Float: 57,221,000
Market Cap: $30.61 million
Optionable: Optionable
Beta: 1.39

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Andrew Spaventa (Age 39)
Founder, CEO, President & Chairperson of the Board
Comp: $685.93k
Dr. David L. Barker Ph.D. (Age 82)
Founder, Member of Scientific Advisory Board & Independent Director
Comp: $63.75k
Dr. Eli N. Glezer Ph.D. (Age 55)
Founder, Chief Scientific Officer & Chair of Scientific Advisory Board
Comp: $496.5k
Mr. Dalen Meeter (Age 46)
Chief Financial Officer
Comp: $434.39k
Jyotsna Ghai
Chief Operating Officer
Mr. Jorge Velarde Jr. (Age 57)
MBA, Senior Vice President of Corporate Development & Strategy
Mr. Jeff Bullard
Head of Sales
Mr. Vincent Brancaccio (Age 41)
Head of Human Resources
Mr. Samuel Ropp Ph.D. (Age 50)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OMIC Stock Analysis - Frequently Asked Questions

Should I buy or sell Singular Genomics Systems stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Singular Genomics Systems in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OMIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMIC, but not buy additional shares or sell existing shares.
View OMIC analyst ratings or view top-rated stocks.
What is Singular Genomics Systems' stock price target for 2024?: 2 brokers have issued 1-year price objectives for Singular Genomics Systems' stock. Their OMIC share price targets range from $0.50 to $0.85. On average, they predict the company's stock price to reach $0.68 in the next twelve months. This suggests a possible upside of 79.0% from the stock's current price.
View analysts price targets for OMIC or view top-rated stocks among Wall Street analysts.
How have OMIC shares performed in 2024?: Singular Genomics Systems' stock was trading at $0.4601 at the beginning of the year. Since then, OMIC shares have decreased by 18.1% and is now trading at $0.3770.
View the best growth stocks for 2024 here.
When is Singular Genomics Systems' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our OMIC earnings forecast.

How were Singular Genomics Systems' earnings last quarter?: Singular Genomics Systems, Inc. (NASDAQ:OMIC) issued its quarterly earnings data on Monday, March, 18th. The company reported ($0.34) earnings per share for the quarter. The company had revenue of $1.08 million for the quarter. Singular Genomics Systems had a negative net margin of 3,257.30% and a negative trailing twelve-month return on equity of 45.33%.
When did Singular Genomics Systems IPO?: Singular Genomics Systems (OMIC) raised $178 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen and UBS Investment Bank served as the underwriters for the IPO.
How do I buy shares of Singular Genomics Systems?: Shares of OMIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OMIC) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Singular Genomics Systems (OMIC) Stock Price, News & Analysis

Singular Genomics Systems MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Singular Genomics Systems Stock (NASDAQ:OMIC)

OMIC Stock Price History

OMIC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

OMIC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™